ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.
NCT00063830
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
INDUSTRY
Sponsor class
Conditions
Ulcerative Colitis
Interventions
DRUG:
Alicaforsen
Sponsor
Ionis Pharmaceuticals, Inc.